Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol

Recently published Austrian study proved that ceramide-based cardiovascular risk test, CERT2, provides more accurate cardiovascular risk prediction than LDL-C.

Read more

Invitation to the Annual General Meeting

Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Thursday, June 30th, 2022 at 10:00…

Read more

Invitation to the Annual General Meeting

Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Tuesday, September 28th, 2021 at 11:00…

Read more

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test

Zora Biosciences Oy announced it has signed a license agreement with Quest Diagnostics, the world leader in diagnostic information services, for Zora’s patented ceramide-analysis technology.

Read more

Zora is part of major European heart disease prevention project

The project is executed together with European Society of Cardiology, ESC, and National Institute for Health and Care Excellence, NICE, as well as cardiologists throughout the Europe.

Read more

LDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients

New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests

Read more

Zora Biosciences Pushing Ceramide Testing to Assess Cardiovascular Risk

Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.

Read more

Zora Brings Molecular Lipids to the Clinic for Cardiovascular Risk Prediction with Enhanced Capacity

Zora’s laboratory has been able to improve its robotized mass spectrometry workflow such that one machine is able to analyze up to 12 000 samples per…

Read more

Zora participates XXXVI Nordic Congress in Clinical Chemistry -congress in June at Helsinki

Zora participates XXXVI Nordic Congress in Clinical Chemistry in June 12-15, 2018 at Helsinki, Finlandia Hall. Nordic Congress in Clinical Chemistry is notable event in…

Read more

New Generation Lipid Test: Are Ceramides New Cholesterol?

Scott Summers from University of Utah discusses at Cell Metabolism Journal, could recently introduced ceramide testing become new cholesterol. Zora has developed a ceramide based…

Read more

Plasma ceramides highlighted in European Heart Journal

European Heart Journal recently highlighted Zora's invention, new blood test that predicts cardiovascular events in patients with or without coronary artery disease. The test is…

Read more

Mayo Clinic will present plasma ceramide results at ACC 2017

The CERAM test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly…

Read more

What are plasma ceramides?

Learn what are plasma ceramides and why you should measure your ceramides. Watch Dr. Jeff Meeusen’s informative video on plasma ceramides and their relation to…

Read more

Heart Attack Risk Test, CERT, is available from various medical centers in Finland

Heart Attack Risk Test, CERT, is available from various medical centers in Finland CERT-test measures persons risk of getting a heart attack or even heart-related…

Read more

Coronary Event Risk Test available in Finland through United Medix Laboratories

Ceramides, Coronary Event Risk Test, CERT Coronary Event Risk Test, CERT, is a new diagnostic test for evaluation of risk of heart attack and CVD-related…

Read more

We are hiring – Join Zora-team

Zora Biosciences is looking for a Bioinformatician Zora Biosciences Oy is a discovery diagnostics company. Zora identifies, validates and develops novel clinical tools using a…

Read more

Plasma Ceramide test is now available at Mayo Clinic Medical Laboratories

Plasma Ceramides predict adverse cardiovascular events. Elevated plasma ceramide concentrations are risk factors for cardiovascular mortality, myocardial infarction and acute coronary syndrome hospitalizations. Plasma ceramides…

Read more

Zora and Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing

Zora and Mayo Medical Laboratories  has signed Collaborate on Plasma Ceramides Testing.  The test will be launched in summer, and is used to predict adverse…

Read more

Zora at EAS 2016 Innsbruck

Zora participates 84th EAS Congress at Innsbruck, Austria. Our CMO Reijo Laaksonen presents our latest results on cardiovascular risk prediction in statin treated patients at…

Read more

Zora at Nature Reviews Research Highlights

Zora's recent publication on CERT was reviewed in Nature Reviews Cardiology Research Highlights. Read the research highlight here.

Read more